Review



cd160-pe clone by55 antibody  (Immunotec inc)

 
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 90
      Buy from Supplier

    Structured Review

    Immunotec inc cd160-pe clone by55 antibody
    MRD detection by CD160FCA and correlation with PCR in the pilot cohort. ( a ) The theoretical MRD expression (calculated, x axis) is plotted against the observed MRD expression (actual analyzed MRD analysis, y axis) by CD160FCA. The results are the percentage expression of <t>CD160</t> of the total leukocyte population. The comparative RT-PCR results are demonstrated at the top of the graph above the corresponding dilution. The R 2 linear regression value for observed expression vs theoretical expression was R 2 =0.98. ( b ) Separation of MRD-positive and MRD-negative populations based on CD160FCA assessment ( P =0.01). ( c ) MRD assessment in paired peripheral blood and bone marrow CLL cells as determined by the CD160FCA ( n =47), irrespective of the treatment regimen (Spearman Rank R =0.87, P <0.0001).
    Cd160 Pe Clone By55 Antibody, supplied by Immunotec inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cd160-pe+clone+by55+antibody/anti+cd160+mab+by55/pmc04314455-72-25-30
    Average 90 stars, based on 1 article reviews
    cd160-pe clone by55 antibody - by Bioz Stars, 2026-10
    90/100 stars

    Images

    1) Product Images from "Minimal residual disease detection with tumor-specific CD160 correlates with event-free survival in chronic lymphocytic leukemia"

    Article Title: Minimal residual disease detection with tumor-specific CD160 correlates with event-free survival in chronic lymphocytic leukemia

    Journal: Blood Cancer Journal

    doi: 10.1038/bcj.2014.92

    MRD detection by CD160FCA and correlation with PCR in the pilot cohort. ( a ) The theoretical MRD expression (calculated, x axis) is plotted against the observed MRD expression (actual analyzed MRD analysis, y axis) by CD160FCA. The results are the percentage expression of CD160 of the total leukocyte population. The comparative RT-PCR results are demonstrated at the top of the graph above the corresponding dilution. The R 2 linear regression value for observed expression vs theoretical expression was R 2 =0.98. ( b ) Separation of MRD-positive and MRD-negative populations based on CD160FCA assessment ( P =0.01). ( c ) MRD assessment in paired peripheral blood and bone marrow CLL cells as determined by the CD160FCA ( n =47), irrespective of the treatment regimen (Spearman Rank R =0.87, P <0.0001).
    Figure Legend Snippet: MRD detection by CD160FCA and correlation with PCR in the pilot cohort. ( a ) The theoretical MRD expression (calculated, x axis) is plotted against the observed MRD expression (actual analyzed MRD analysis, y axis) by CD160FCA. The results are the percentage expression of CD160 of the total leukocyte population. The comparative RT-PCR results are demonstrated at the top of the graph above the corresponding dilution. The R 2 linear regression value for observed expression vs theoretical expression was R 2 =0.98. ( b ) Separation of MRD-positive and MRD-negative populations based on CD160FCA assessment ( P =0.01). ( c ) MRD assessment in paired peripheral blood and bone marrow CLL cells as determined by the CD160FCA ( n =47), irrespective of the treatment regimen (Spearman Rank R =0.87, P <0.0001).

    Techniques Used: Expressing, Reverse Transcription Polymerase Chain Reaction

    MRD detection by CD160FCA vs International Standardized Protocols in the validation cohort. ( a ) Comparative assessment of CD160FCA MRD positivity as a percentage of total leucocytes against the ISA methodology ( n =48 samples, P <0.001, R =0.91). ( b ) MRD-positive and -negative cohorts based on the median fluorescence intensity (MFI) of the CD2 neg /CD5 + /CD19 + /CD23 + /CD160 + population.
    Figure Legend Snippet: MRD detection by CD160FCA vs International Standardized Protocols in the validation cohort. ( a ) Comparative assessment of CD160FCA MRD positivity as a percentage of total leucocytes against the ISA methodology ( n =48 samples, P <0.001, R =0.91). ( b ) MRD-positive and -negative cohorts based on the median fluorescence intensity (MFI) of the CD2 neg /CD5 + /CD19 + /CD23 + /CD160 + population.

    Techniques Used: Biomarker Discovery, Fluorescence

    Related Articles

    Expressing:

    Article Title: Minimal residual disease detection with tumor-specific CD160 correlates with event-free survival in chronic lymphocytic leukemia
    Article Snippet: The CD160FCA incorporates CD2-FITC (Clone S5.2), CD5-APC (Clone L17F12), CD19-PerCP cy5.5 (Clone SJ25C1), CD23-APC (Clone EBVCS-5) and CD45 V500 (Clone Hi30) (BD Biosciences, Oxford, UK); CD160-PE (Clone BY55; IgM isotype; Immunotech, Beckman Coulter, Marseilles, France).

    Reverse Transcription Polymerase Chain Reaction:

    Article Title: Minimal residual disease detection with tumor-specific CD160 correlates with event-free survival in chronic lymphocytic leukemia
    Article Snippet: The CD160FCA incorporates CD2-FITC (Clone S5.2), CD5-APC (Clone L17F12), CD19-PerCP cy5.5 (Clone SJ25C1), CD23-APC (Clone EBVCS-5) and CD45 V500 (Clone Hi30) (BD Biosciences, Oxford, UK); CD160-PE (Clone BY55; IgM isotype; Immunotech, Beckman Coulter, Marseilles, France).

    Biomarker Discovery:

    Article Title: Minimal residual disease detection with tumor-specific CD160 correlates with event-free survival in chronic lymphocytic leukemia
    Article Snippet: The CD160FCA incorporates CD2-FITC (Clone S5.2), CD5-APC (Clone L17F12), CD19-PerCP cy5.5 (Clone SJ25C1), CD23-APC (Clone EBVCS-5) and CD45 V500 (Clone Hi30) (BD Biosciences, Oxford, UK); CD160-PE (Clone BY55; IgM isotype; Immunotech, Beckman Coulter, Marseilles, France).

    Fluorescence:

    Article Title: Minimal residual disease detection with tumor-specific CD160 correlates with event-free survival in chronic lymphocytic leukemia
    Article Snippet: The CD160FCA incorporates CD2-FITC (Clone S5.2), CD5-APC (Clone L17F12), CD19-PerCP cy5.5 (Clone SJ25C1), CD23-APC (Clone EBVCS-5) and CD45 V500 (Clone Hi30) (BD Biosciences, Oxford, UK); CD160-PE (Clone BY55; IgM isotype; Immunotech, Beckman Coulter, Marseilles, France).



    Similar Products

    cd160-pe clone by55 antibody  (Immunotec inc)
    90
    Immunotec inc cd160-pe clone by55 antibody
    MRD detection by CD160FCA and correlation with PCR in the pilot cohort. ( a ) The theoretical MRD expression (calculated, x axis) is plotted against the observed MRD expression (actual analyzed MRD analysis, y axis) by CD160FCA. The results are the percentage expression of <t>CD160</t> of the total leukocyte population. The comparative RT-PCR results are demonstrated at the top of the graph above the corresponding dilution. The R 2 linear regression value for observed expression vs theoretical expression was R 2 =0.98. ( b ) Separation of MRD-positive and MRD-negative populations based on CD160FCA assessment ( P =0.01). ( c ) MRD assessment in paired peripheral blood and bone marrow CLL cells as determined by the CD160FCA ( n =47), irrespective of the treatment regimen (Spearman Rank R =0.87, P <0.0001).
    Cd160 Pe Clone By55 Antibody, supplied by Immunotec inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cd160-pe+clone+by55+antibody/anti+cd160+mab+by55/pmc04314455-72-25-30
    Average 90 stars, based on 1 article reviews
    cd160-pe clone by55 antibody - by Bioz Stars, 2026-10
    90/100 stars
    		  Buy from Supplier

    Image Search Results


    MRD detection by CD160FCA and correlation with PCR in the pilot cohort. ( a ) The theoretical MRD expression (calculated, x axis) is plotted against the observed MRD expression (actual analyzed MRD analysis, y axis) by CD160FCA. The results are the percentage expression of CD160 of the total leukocyte population. The comparative RT-PCR results are demonstrated at the top of the graph above the corresponding dilution. The R 2 linear regression value for observed expression vs theoretical expression was R 2 =0.98. ( b ) Separation of MRD-positive and MRD-negative populations based on CD160FCA assessment ( P =0.01). ( c ) MRD assessment in paired peripheral blood and bone marrow CLL cells as determined by the CD160FCA ( n =47), irrespective of the treatment regimen (Spearman Rank R =0.87, P <0.0001).

    Journal: Blood Cancer Journal

    Article Title: Minimal residual disease detection with tumor-specific CD160 correlates with event-free survival in chronic lymphocytic leukemia

    doi: 10.1038/bcj.2014.92

    Figure Lengend Snippet: MRD detection by CD160FCA and correlation with PCR in the pilot cohort. ( a ) The theoretical MRD expression (calculated, x axis) is plotted against the observed MRD expression (actual analyzed MRD analysis, y axis) by CD160FCA. The results are the percentage expression of CD160 of the total leukocyte population. The comparative RT-PCR results are demonstrated at the top of the graph above the corresponding dilution. The R 2 linear regression value for observed expression vs theoretical expression was R 2 =0.98. ( b ) Separation of MRD-positive and MRD-negative populations based on CD160FCA assessment ( P =0.01). ( c ) MRD assessment in paired peripheral blood and bone marrow CLL cells as determined by the CD160FCA ( n =47), irrespective of the treatment regimen (Spearman Rank R =0.87, P <0.0001).

    Article Snippet: The CD160FCA incorporates CD2-FITC (Clone S5.2), CD5-APC (Clone L17F12), CD19-PerCP cy5.5 (Clone SJ25C1), CD23-APC (Clone EBVCS-5) and CD45 V500 (Clone Hi30) (BD Biosciences, Oxford, UK); CD160-PE (Clone BY55; IgM isotype; Immunotech, Beckman Coulter, Marseilles, France).

    Techniques: Expressing, Reverse Transcription Polymerase Chain Reaction

    MRD detection by CD160FCA vs International Standardized Protocols in the validation cohort. ( a ) Comparative assessment of CD160FCA MRD positivity as a percentage of total leucocytes against the ISA methodology ( n =48 samples, P <0.001, R =0.91). ( b ) MRD-positive and -negative cohorts based on the median fluorescence intensity (MFI) of the CD2 neg /CD5 + /CD19 + /CD23 + /CD160 + population.

    Journal: Blood Cancer Journal

    Article Title: Minimal residual disease detection with tumor-specific CD160 correlates with event-free survival in chronic lymphocytic leukemia

    doi: 10.1038/bcj.2014.92

    Figure Lengend Snippet: MRD detection by CD160FCA vs International Standardized Protocols in the validation cohort. ( a ) Comparative assessment of CD160FCA MRD positivity as a percentage of total leucocytes against the ISA methodology ( n =48 samples, P <0.001, R =0.91). ( b ) MRD-positive and -negative cohorts based on the median fluorescence intensity (MFI) of the CD2 neg /CD5 + /CD19 + /CD23 + /CD160 + population.

    Article Snippet: The CD160FCA incorporates CD2-FITC (Clone S5.2), CD5-APC (Clone L17F12), CD19-PerCP cy5.5 (Clone SJ25C1), CD23-APC (Clone EBVCS-5) and CD45 V500 (Clone Hi30) (BD Biosciences, Oxford, UK); CD160-PE (Clone BY55; IgM isotype; Immunotech, Beckman Coulter, Marseilles, France).

    Techniques: Biomarker Discovery, Fluorescence